This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Orchard Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Orchard Therapeutics은 연평균 12.3%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 24.8%의 비율로 수입이 증가했습니다. 매출은 연평균 57.1%의 비율로 증가했습니다.

주요 정보

12.3%

수익 성장률

63.6%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	57.1%
자기자본 수익률	-90.9%
순이익	-333.9%
최근 수익 업데이트	30 Sep 2023

최근 과거 실적 업데이트

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

수익 및 비용 분석

Orchard Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:ORTX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 23	22	-73	44	0
30 Jun 23	21	-85	44	0
31 Mar 23	18	-124	47	0
31 Dec 22	23	-151	49	0
30 Sep 22	16	-179	51	0
30 Jun 22	12	-168	53	0
31 Mar 22	7	-154	53	0
31 Dec 21	2	-145	54	0
30 Sep 21	1	-142	57	0
30 Jun 21	2	-126	57	-50
31 Mar 21	3	-137	58	-25
31 Dec 20	3	-152	61	0
30 Sep 20	3	-164	63	31
30 Jun 20	3	-180	65	109
31 Mar 20	3	-183	63	125
31 Dec 19	3	-163	57	117
30 Sep 19	3	-143	51	237
30 Jun 19	2	-140	44	103
31 Mar 19	2	-246	38	214
31 Dec 18	2	-230	31	205
30 Sep 18	1	-219	21	65
30 Jun 18	0	-198	16	182
31 Mar 18	0	-48	9	36
31 Dec 17	0	-40	6	33

양질의 수익: ORTX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ORTX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ORTX 은(는) 수익성이 없지만 지난 5년 동안 연간 12.3% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 ORTX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ORTX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 36.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ORTX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -90.86% )을 갖습니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/01/24 05:56
장 마감 주가	2024/01/24 00:00
수익	2023/09/30
연간 수익	2022/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Orchard Therapeutics plc 10 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Charles Duncan	Cantor Fitzgerald & Co.
Emma Nealon	Cantor Fitzgerald & Co.
Graig Suvannavejh	Goldman Sachs

This company has been acquired

Orchard Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020)

Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019)

Recent updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

New major risk - Financial position

Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023

Price target decreased by 25% to US$16.00

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

New major risk - Share price stability

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023

Consensus estimates of losses per share improve by 55%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to US$1.61 loss

Consensus EPS estimates upgraded to US$1.81 loss

Consensus revenue estimates decrease by 18%, EPS upgraded

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Price target decreased by 28% to US$21.60

Price target decreased by 8.7% to US$27.40

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Price target decreased to US$3.67

Insufficient new directors

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Consensus forecasts updated

Price target decreased to US$3.67

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Price target decreased to US$3.67

Price target decreased to US$4.00

Insufficient new directors

Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates increase by 37%

Price target decreased to US$8.64

Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD

Orchard Therapeutics: Shadow Of Former Glory

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020)

Price target decreased to US$10.31

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

Consensus forecasts updated

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Consensus forecasts updated

Price target decreased to US$11.70

Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V.

Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Price target decreased to US$13.00

Consensus forecasts updated

Independent Non-Executive Director Jon Ellis has left the company

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Orchard Therapeutics Announces Data Published in the New England Journal of Medicine Evaluating the Safety and Efficacy of Investigational Gene Therapy Products, Including OTL-101

Consensus revenue estimates fall to US$11.5m

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™

Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019)

Revenue behind estimates

Orchard Therapeutics plc Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome

Orchard Therapeutics plc announced that it expects to receive $149.999996 million in funding from RA Capital Management, L.P., Avidity Partners Management LP, Casdin Capital, LLC, Farallon Capital Management, L.L.C., Citadel Enterprise Americas LLC and other investors